Francesca Bargiacchi, PhD

Francesca Bargiacchi, PhD, is Executive Director of Global Medical Affairs for Solid Tumors at Menarini-Stemline, where she leads pan-European medical strategy and field medical operations across Phase III registrational programs in breast cancer. She brings over 20 years of oncology experience spanning bench research, clinical development, and medical affairs leadership, including foundational HER2+ breast cancer research at Genentech that contributed to the scientific understanding underpinning today's standard-of-care therapies. Her subsequent roles at Eli Lilly, Merck, Blueprint Medicines, and Relay Therapeutics have focused on advancing treatment options for women with breast and gynecologic cancers through evidence generation, launch excellence, and KOL engagement across the US and Europe. A breast cancer survivor herself, Francesca brings both scientific rigor and lived patient perspective to the policy and access conversations shaping outcomes for women across Europe. She holds a PhD in Pharmacology from the University of North Carolina School of Medicine.